Unknown PHASE2 INTERVENTIONAL NCT00639119

Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type

Sponsor: University of Turku

Interventions Ropinirole

Updated 6 times since 2017 Last updated: Mar 18, 2008 Started: Aug 31, 2007 Primary completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00639119, this PHASE2 trial focuses on Unverricht-Lundborg Syndrome and remains ongoing. Sponsored by University of Turku, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Enrolling By Invitation → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Turku

Data source: University of Turku

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Turku, Finland